Lupin rises on getting USFDA’s tentative approval for Brivaracetam Tablets

17 Aug 2021 Evaluate

Lupin is currently trading at Rs. 977.10, up by 9.80 points or 1.01% from its previous closing of Rs. 967.30 on the BSE.

The scrip opened at Rs. 979.80 and has touched a high and low of Rs. 981.45 and Rs. 972.70 respectively. So far 20517 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1267.50 on 02-Jun-2021 and a 52 week low of Rs. 856.00 on 10-Nov-2020.

Last one week high and low of the scrip stood at Rs. 1090.60 and Rs. 953.75 respectively. The current market cap of the company is Rs. 43911.88 crore.

The promoters holding in the company stood at 46.84%, while Institutions and Non-Institutions held 40.69% and 12.47% respectively.

Lupin has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Brivaracetam Tablets, 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg, to market a generic equivalent of Briviact Tablets, 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg, of UCB Inc.

This product will be manufactured at Lupin’s Nagpur facility in India. Brivaracetam Tablets are indicated for the treatment of partial-onset seizures in patients four years of age and older. Brivaracetam Tablets (RLD: Briviact Tablets) had estimated annual sales of $311 million in the U.S. (IQVIA MAT June 2021).

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.

Lupin Share Price

2151.05 19.25 (0.90%)
30-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1595.00
Dr. Reddys Lab 1218.40
Cipla 1323.95
Zydus Lifesciences 885.20
Lupin 2151.05
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×